Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

6.7%

3 terminated/withdrawn out of 45 trials

Success Rate

91.9%

+5.4% vs industry average

Late-Stage Pipeline

31%

14 trials in Phase 3/4

Results Transparency

32%

11 of 34 completed trials have results

Key Signals

2 recruiting11 with results

Enrollment Performance

Analytics

Phase 1

14(31.8%)

Phase 3

14(31.8%)

Phase 2

13(29.5%)

Early Phase 1

2(4.5%)

N/A

1(2.3%)

44Total

Phase 1(14)

Phase 3(14)

Phase 2(13)

Early Phase 1(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (45)

Showing 20 of 45 trials

NCT07197944Phase 3Recruiting

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Role: lead

NCT07338214Phase 1Completed

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

Role: lead

NCT06662539Phase 2Completed

Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbidities

Role: lead

NCT06682975Phase 1Recruiting

A Research Study Looking at the Safety of Single and Multiple Doses of ZP9830 and How it Works in the Body of Healthy Participants

Role: lead

NCT04881825Phase 3Active Not Recruiting

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Role: lead

NCT07228403Phase 3Enrolling By Invitation

Efficacy and Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome

Role: lead

NCT03905707Phase 3Active Not Recruiting

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Role: lead

NCT07076030Phase 1Completed

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

Role: lead

NCT03941236Phase 3Active Not Recruiting

Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism

Role: lead

NCT06926842Phase 2Active Not Recruiting

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Role: lead

NCT05378672Phase 3Completed

A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D

Role: lead

NCT03690206Phase 3Completed

Efficacy And Safety Evaluation of Glepaglutide in Treatment of Short Bowel Syndrome (SBS)

Role: lead

NCT06758583Phase 1Completed

A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Role: lead

NCT06000891Phase 1Terminated

A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570

Role: lead

NCT04172441Phase 2Completed

Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Role: lead

NCT05788601Phase 2Active Not Recruiting

Dapiglutide for the Treatment of Obesity

Role: collaborator

NCT04991311Phase 3Completed

The Long-term Effect on Intestinal Absorption and Safety of Treatment With Glepaglutide in Patients With Short Bowel Syndrome

Role: lead

NCT05613387Phase 1Completed

A Research Study Looking at the Safety of Multiple Doses of ZP8396 and How it Works in the Body of Healthy Participants

Role: lead

NCT03777176Phase 3Completed

A Two-Period Open-label Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism

Role: lead

NCT04824872Phase 2Withdrawn

Efficacy and Safety of Dasiglucagon for Treatment of Post-bariatric Hypoglycemia in Roux-en-Y Gastric Bypass (RYGB) Operated Adults

Role: lead